U.S. Intravenous Immunoglobulin Market Size & Outlook
U.S. intravenous immunoglobulin market, 2018-2030 (US$M)
Related Markets
U.S. intravenous immunoglobulin market highlights
- The U.S. intravenous immunoglobulin market generated a revenue of USD 5,123.5 million in 2024 and is expected to reach USD 7,517.3 million by 2030.
- The U.S. market is expected to grow at a CAGR of 6.6% from 2025 to 2030.
- In terms of segment, immunodeficiency diseases was the largest revenue generating application in 2024.
- Kawasaki Disease is the most lucrative application segment registering the fastest growth during the forecast period.
Intravenous immunoglobulin market data book summary
| Market revenue in 2024 | USD 5,123.5 million |
| Market revenue in 2030 | USD 7,517.3 million |
| Growth rate | 6.6% (CAGR from 2025 to 2030) |
| Largest segment | Immunodeficiency diseases |
| Fastest growing segment | Kawasaki Disease |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome |
| Key market players worldwide | Biotest AG ADR, Baxter International Inc, Grifols SA Ordinary Shares - Class A, CSL Ltd, Octapharma AG, LFB (Laboratoire Français du Fractionnement et des Biotechnologies), Taibang Biological Group, Kedrion Biopharma |
Other key industry trends
- In terms of revenue, U.S. accounted for 37.0% of the global intravenous immunoglobulin market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. intravenous immunoglobulin market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 1,191.4 million by 2030.
Immunodeficiency diseases was the largest segment with a revenue share of 20.88% in 2024. Horizon Databook has segmented the U.S. intravenous immunoglobulin market based on immunodeficiency diseases, cidp, hypogammaglobulinemia, congenital aids, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, itp, kawasaki disease, guillain-barre syndrome covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. continues to dominate the North American market, holding a share of 80.19% in 2024. The growth in the U.S. IVIG market is largely attributed to the increasing prevalence of immunodeficiency diseases and related health conditions. CIDP, Hypogammaglobulinemia, and autoimmune disorders such as Myasthenia Gravis and ITP are becoming more common, driving the demand for IVIG therapies.
Additionally, hospital pharmacies and specialty pharmacies remain key distribution points for IVIG therapies in the U.S., where both providers and patients benefit from advanced treatments offered by major suppliers such as Biotest AG, Baxter, and Octapharma AG.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intravenous Immunoglobulin Market Scope
Intravenous Immunoglobulin Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. intravenous immunoglobulin market size, by application, 2018-2030 (US$M)
U.S. Intravenous Immunoglobulin Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
